No surrender: A group of marquee biotech players bets on the $350M PhIII resurrection story of a heavyweight contender

Bioregnum Opinion Column by John Carroll

Anyone reading Biogen’s press release on the flat failure of dexpramipexole in treating ALS couldn’t overlook the note of finality then R&D chief Doug Williams used to mark its grave 10 years ago. The drug failed the primary endpoint….